Labiotech.eu

More News! 17 May 2018

The First In-Human Trial of an Eye Implant Helps Patients With Glaucoma

iSTAR Medical has obtained promising results from the first-in-human trial of an eye implant, that can decrease fluid pressure in the eyes of glaucoma patients. iSTAR Medical, a Belgian biotech, has six-month results from a first-in-human trial showing the effects of its device on intraocular pressure in patients with glaucoma — a condition where high eye […]

May 17, 2018 - 2 minutesmins - By Alexander Burik

More News! 17 May 2018

After settling lawsuit with Bayer, Cellectis spin-off launches €41M follow-on offering

Cellectis spin-off Calyxt has launched a €41M follow-on round after settling the lawsuit it recently brought against Bayer CropScience, for breach of a license agreement for access to patents for its TALEN technology. The French biotech Cellectis owns 79.1% of the ag biotech’s outstanding shares. Cellectis is well-known for its gene editing tool TALEN. However, while it focuses […]

May 17, 2018 - 2 minutesmins - By Helen Albert

News and Trends 16 May 2018

Swedish Biotech Partners With Novo Nordisk to Advance Stem Cell Therapies for Diabetes

BioLamina has partnered with Novo Nordisk to develop stem cell therapies for diabetes and other conditions using a unique cell culture matrix technology. BioLamina, based in Stockholm, is collaborating with the world-leader in diabetes treatment Novo Nordisk to develop stem cell therapies that use BioLamina’s protein cell culture matrices. BioLamina’s technology could enhance Novo Nordisk’s […]

May 16, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 16 May 2018

Actelion’s Billion-Euro Spin-Off Starts First Phase III Trial in its Pipeline

Idorsia has started the first Phase III study in its pipeline to test the drug in patients with a life-threatening genetic disorder, which could bring the company closer to a market launch and profitability. Swiss biotech Idorsia has started a Phase III trial testing its lead compound in patients with Fabry disease, a life-threatening genetic disorder […]

May 16, 2018 - 3 minutesmins - By Alexander Burik

News and Trends 15 May 2018

Series B Funding Helps Dutch Biotech Fight Graft Versus Host Disease

Xenikos has raised $30M (€25M) in Series B funding to conduct Phase III trials for its treatment for acute graft-versus-host disease, a complication of stem cell transplants. Xenikos has raised a substantial Series B fundraising round to conduct Phase III trials in the US and the EU for T-Guard, its treatment for steroid-resistant acute graft […]

May 15, 2018 - 2 minutesmins - By Alexander Burik

Best in Biotech 15 May 2018

Here Are 10 of the Hottest Biotech Hubs in Europe

Biotech is rapidly gaining traction in Europe. To help those trying to pick one of the many biotech hubs in Europe, I have compiled a list of where some of the most exciting biotech companies are based. Currently, biotech is one of the biggest employers in Europe. Whether you love big cities full of opportunities […]

May 15, 2018 - 10 minutesmins - By Clara Rodríguez Fernández

News and Trends 15 May 2018

Swiss Company Raises Ambitious IPO to Fight Antibiotic Resistance

Polyphor has closed an IPO of CHF 165M (€138M) to continue developing a new class of antibiotics against pneumonia, as well as treatments for cystic fibrosis and breast cancer. Polyphor, based in Switzerland, has raised a substantial IPO of CHF 165M (€138M) on the SIX Swiss Exchange, surpassing its initial goal of CHF150M (€127M). The funds will […]

May 15, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 15 May 2018

An Epigenetic Drug for Prostate Cancer Gets $26M to Enter Clinical Trials

CellCentric has raised a private round to fund the development of a first-in-class drug with potential to tackle treatment-resistant prostate cancer. Cambridge-based CellCentric has raised $26M from Morningside Venture Investments. The company plans to use the cash to fund the development of an epigenetic cancer drug up to Phase 2b trials. The drug in question, called CCS1477, […]

May 15, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 14 May 2018

German Biotech Expands Oncology Deal with Bluebird bio to $1.5Bn

Medigene and bluebird bio are increasing the number of cancer targets against which to develop TCR candidates, raising their already huge deal to a massive $1.5Bn. In September 2016, Medigene and bluebird bio partnered to develop T cell receptor-modified T cells (TCR-Ts) as candidates for cancer immunotherapy treatments. Medigene was offered up to $250M per each of […]

May 14, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

In Depth 14 May 2018

Could Stem Cells Replace Animal Testing in Drug Development?

Animal testing is a crucial part of developing new medicines, but it comes with ethical concerns. Stem cells could eventually make it unnecessary. Nowadays you can order a rat with Parkinson’s disease or a dog with diabetes as you would any product on the internet. But the ethical issues surrounding animal testing beg the question: […]

May 14, 2018 - 6 minutesmins - By Timothé Cynober

Startup Scout 11 May 2018

This Oxford Biotech is Using DNA to Find New Peptide Drugs

Today, we’re in Oxford, UK, visiting Orbit Discovery. The biotech develops peptide drugs for chronic diseases using DNA to tag potential therapeutic proteins. Mission: Orbit Discovery develops peptide drugs for a range of conditions including metabolic, autoimmune and cardiovascular diseases using beads to connect peptides to the DNA that encodes them and see how well the peptides […]

May 11, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 9 May 2018

Swiss Spin-off Secures Funding for Antibodies to Reach Difficult Targets

Memo Therapeutics has raised CHF 5M (€4,2M) to develop its antibody detection technology, which uses whole antibodies to reach difficult targets. Memo Therapeutics, a spin-off from ETH Zurich, has closed a Series A2 round of CHF 5M (€4,2M). The funding was provided by Redalpine Venture Partners and Zurich Cantonal Bank among other investors and will […]

May 9, 2018 - 1 minutemin - By Alexander Burik

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The First In-Human Trial of an Eye Implant Helps Patients With Glaucoma

After settling lawsuit with Bayer, Cellectis spin-off launches €41M follow-on offering

Swedish Biotech Partners With Novo Nordisk to Advance Stem Cell Therapies for Diabetes

Actelion’s Billion-Euro Spin-Off Starts First Phase III Trial in its Pipeline

Series B Funding Helps Dutch Biotech Fight Graft Versus Host Disease

Here Are 10 of the Hottest Biotech Hubs in Europe

Swiss Company Raises Ambitious IPO to Fight Antibiotic Resistance

An Epigenetic Drug for Prostate Cancer Gets $26M to Enter Clinical Trials

German Biotech Expands Oncology Deal with Bluebird bio to $1.5Bn

Could Stem Cells Replace Animal Testing in Drug Development?

This Oxford Biotech is Using DNA to Find New Peptide Drugs

Swiss Spin-off Secures Funding for Antibodies to Reach Difficult Targets

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!